Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2025-03-07 00:00:00 ET · period of report 2025-03-07 · accession 0001628280-25-011338 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-07 | 2025-03-07 | SUPN | Khattar Jack A. | Pres, CEO, Dir | M - OptEx | $0.00 | +38.6K | 992.2K | +4% | $0 |
| D | 2025-03-07 | 2025-03-07 | SUPN | Khattar Jack A. | Pres, CEO, Dir | F - Tax | $39.11 | -18.6K | 973.6K | -2% | -$726.7K |
| D | 2025-03-07 | 2025-03-07 | SUPN | Khattar Jack A. | Pres, CEO, Dir | M - OptEx | $0.00 | -38.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-07 | M | A | 38,640 | $0.00 | 992,219 | D | — | — | (F1) Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 17, 2025. |
| 2 | Common | Common Stock | 2025-03-07 | F | D | 18,581 | $39.11 | 973,638 | D | — | — | (F2) Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| 3 | Derivative | Performance Share Units | 2025-03-07 | M | D | 38,640 | $0.00 | 0 | D | $0.00 · — to — | 38,640 Common Stock | (F3) On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. |